CA2897673A1

CA2897673A1 - Method for treating cancer based on level of a nucleoside transporter

Method for treating cancer based on level of a nucleoside transporter Download PDF

Info

Publication number: CA2897673A1
Authority: CA; Canada
Prior art keywords: individual; cancer; level; paclitaxel; composition
Prior art date: 2013-01-11
Legal status : Abandoned

Application number

CA2897673A

Other languages

English (en)

French (fr)

Inventor

Carla Heise

Current Assignee

Abraxis Bioscience LLC

Original Assignee

Abraxis Bioscience LLC

Priority date

2013-01-11

Filing date

2014-01-10

Publication date

2014-07-17

2014-01-10 Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC

2014-07-17 Publication of CA2897673A1 publication Critical patent/CA2897673A1/en

Status Abandoned legal-status Critical Current

Links

108091006527 nucleoside transporters Proteins 0.000 title claims abstract description 304
238000000034 method Methods 0.000 title claims abstract description 302
102000019055 Nucleoside Transport Proteins Human genes 0.000 title claims abstract description 278
206010028980 Neoplasm Diseases 0.000 title claims abstract description 264
201000011510 cancer Diseases 0.000 title claims abstract description 185
239000000203 mixture Substances 0.000 claims abstract description 397
239000002105 nanoparticle Substances 0.000 claims abstract description 354
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 329
229960001592 paclitaxel Drugs 0.000 claims abstract description 322
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 274
229960005277 gemcitabine Drugs 0.000 claims abstract description 271
229930012538 Paclitaxel Natural products 0.000 claims abstract description 237
239000002777 nucleoside Substances 0.000 claims abstract description 210
150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 204
102000009027 Albumins Human genes 0.000 claims abstract description 203
108010088751 Albumins Proteins 0.000 claims abstract description 203
229940123237 Taxane Drugs 0.000 claims description 252
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 249
238000011282 treatment Methods 0.000 claims description 191
108091006905 Human Serum Albumin Proteins 0.000 claims description 99
102000008100 Human Serum Albumin Human genes 0.000 claims description 99
230000014509 gene expression Effects 0.000 claims description 48
241000282414 Homo sapiens Species 0.000 claims description 33
108090000623 proteins and genes Proteins 0.000 claims description 30
108020004999 messenger RNA Proteins 0.000 claims description 26
239000003795 chemical substances by application Substances 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 25
238000012308 immunohistochemistry method Methods 0.000 claims description 6
206010061902 Pancreatic neoplasm Diseases 0.000 description 173
201000002528 pancreatic cancer Diseases 0.000 description 168
208000008443 pancreatic carcinoma Diseases 0.000 description 165
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 164
101000822020 Homo sapiens Equilibrative nucleoside transporter 1 Proteins 0.000 description 155
102000045714 human SLC29A1 Human genes 0.000 description 154
108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 85
210000004027 cell Anatomy 0.000 description 63
239000000523 sample Substances 0.000 description 52
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
201000010099 disease Diseases 0.000 description 48
-1 GEMZAR0) Chemical compound 0.000 description 45
239000013068 control sample Substances 0.000 description 44
238000002560 therapeutic procedure Methods 0.000 description 37
238000010186 staining Methods 0.000 description 35
201000001441 melanoma Diseases 0.000 description 34
230000003442 weekly effect Effects 0.000 description 30
239000003814 drug Substances 0.000 description 29
206010061289 metastatic neoplasm Diseases 0.000 description 28
230000004044 response Effects 0.000 description 28
230000004083 survival effect Effects 0.000 description 28
230000000694 effects Effects 0.000 description 27
230000001394 metastastic effect Effects 0.000 description 27
102100021472 Equilibrative nucleoside transporter 3 Human genes 0.000 description 25
102100036908 Equilibrative nucleoside transporter 4 Human genes 0.000 description 25
101000822041 Homo sapiens Equilibrative nucleoside transporter 3 Proteins 0.000 description 25
101000713320 Homo sapiens Equilibrative nucleoside transporter 4 Proteins 0.000 description 25
101710100111 SPARC Proteins 0.000 description 25
102100037599 SPARC Human genes 0.000 description 25
102000037831 nucleoside transporters Human genes 0.000 description 24
229940079593 drug Drugs 0.000 description 23
206010035226 Plasma cell myeloma Diseases 0.000 description 21
206010060862 Prostate cancer Diseases 0.000 description 19
208000000236 Prostatic Neoplasms Diseases 0.000 description 19
210000000496 pancreas Anatomy 0.000 description 19
208000006265 Renal cell carcinoma Diseases 0.000 description 18
206010027476 Metastases Diseases 0.000 description 17
208000034578 Multiple myelomas Diseases 0.000 description 17
238000001990 intravenous administration Methods 0.000 description 17
230000009401 metastasis Effects 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
102100023116 Sodium/nucleoside cotransporter 1 Human genes 0.000 description 16
208000009956 adenocarcinoma Diseases 0.000 description 16
230000003902 lesion Effects 0.000 description 16
238000009472 formulation Methods 0.000 description 15
206010006187 Breast cancer Diseases 0.000 description 14
238000003364 immunohistochemistry Methods 0.000 description 14
101000685663 Homo sapiens Sodium/nucleoside cotransporter 1 Proteins 0.000 description 13
101000821827 Homo sapiens Sodium/nucleoside cotransporter 2 Proteins 0.000 description 13
101000822028 Homo sapiens Solute carrier family 28 member 3 Proteins 0.000 description 13
102100021541 Sodium/nucleoside cotransporter 2 Human genes 0.000 description 13
102100021470 Solute carrier family 28 member 3 Human genes 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
208000026310 Breast neoplasm Diseases 0.000 description 12
230000008901 benefit Effects 0.000 description 12
239000000725 suspension Substances 0.000 description 12
201000009030 Carcinoma Diseases 0.000 description 11
238000002648 combination therapy Methods 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 10
238000001802 infusion Methods 0.000 description 10
230000036961 partial effect Effects 0.000 description 10
206010003571 Astrocytoma Diseases 0.000 description 9
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 9
238000011161 development Methods 0.000 description 9
230000009467 reduction Effects 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
206010058467 Lung neoplasm malignant Diseases 0.000 description 8
206010025323 Lymphomas Diseases 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
208000005017 glioblastoma Diseases 0.000 description 8
238000001356 surgical procedure Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
206010018338 Glioma Diseases 0.000 description 7
206010027480 Metastatic malignant melanoma Diseases 0.000 description 7
206010061535 Ovarian neoplasm Diseases 0.000 description 7
206010041067 Small cell lung cancer Diseases 0.000 description 7
206010043276 Teratoma Diseases 0.000 description 7
238000001574 biopsy Methods 0.000 description 7
201000005202 lung cancer Diseases 0.000 description 7
208000020816 lung neoplasm Diseases 0.000 description 7
231100000682 maximum tolerated dose Toxicity 0.000 description 7
208000021039 metastatic melanoma Diseases 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000004043 responsiveness Effects 0.000 description 7
108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 6
206010061818 Disease progression Diseases 0.000 description 6
102000018428 Equilibrative nucleoside transporters Human genes 0.000 description 6
108050007554 Equilibrative nucleoside transporters Proteins 0.000 description 6
208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 6
229940028652 abraxane Drugs 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000005750 disease progression Effects 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000035772 mutation Effects 0.000 description 6
208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
230000000683 nonmetastatic effect Effects 0.000 description 6
125000003835 nucleoside group Chemical group 0.000 description 6
239000008389 polyethoxylated castor oil Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
208000003174 Brain Neoplasms Diseases 0.000 description 5
102000014778 Concentrative nucleoside transporters Human genes 0.000 description 5
108050005111 Concentrative nucleoside transporters Proteins 0.000 description 5
206010014967 Ependymoma Diseases 0.000 description 5
208000032612 Glial tumor Diseases 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
206010033128 Ovarian cancer Diseases 0.000 description 5
208000007452 Plasmacytoma Diseases 0.000 description 5
206010038389 Renal cancer Diseases 0.000 description 5
230000005856 abnormality Effects 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000012736 aqueous medium Substances 0.000 description 5
239000008366 buffered solution Substances 0.000 description 5
208000002458 carcinoid tumor Diseases 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
208000019420 lymphoid neoplasm Diseases 0.000 description 5
208000037819 metastatic cancer Diseases 0.000 description 5
208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
230000002980 postoperative effect Effects 0.000 description 5
208000000587 small cell lung carcinoma Diseases 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000011277 treatment modality Methods 0.000 description 5
KKZRPIKZBFQAKR-YPWTWYSKSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KKZRPIKZBFQAKR-YPWTWYSKSA-N 0.000 description 4
208000012526 B-cell neoplasm Diseases 0.000 description 4
208000008839 Kidney Neoplasms Diseases 0.000 description 4
208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 4
208000000172 Medulloblastoma Diseases 0.000 description 4
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 4
206010061328 Ovarian epithelial cancer Diseases 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000012472 biological sample Substances 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
208000030381 cutaneous melanoma Diseases 0.000 description 4
230000001066 destructive effect Effects 0.000 description 4
230000002124 endocrine Effects 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
238000009093 first-line therapy Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
210000003128 head Anatomy 0.000 description 4
238000001794 hormone therapy Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
201000010982 kidney cancer Diseases 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
208000037821 progressive disease Diseases 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
208000005893 serous cystadenoma Diseases 0.000 description 4
238000009097 single-agent therapy Methods 0.000 description 4
206010041823 squamous cell carcinoma Diseases 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 3
102000052609 BRCA2 Human genes 0.000 description 3
108700020462 BRCA2 Proteins 0.000 description 3
101150008921 Brca2 gene Proteins 0.000 description 3
206010055113 Breast cancer metastatic Diseases 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
206010007953 Central nervous system lymphoma Diseases 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
208000009798 Craniopharyngioma Diseases 0.000 description 3
208000001154 Dermoid Cyst Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 3
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
102100021469 Equilibrative nucleoside transporter 1 Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000000164 Familial pancreatic carcinoma Diseases 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 3
235000010643 Leucaena leucocephala Nutrition 0.000 description 3
240000007472 Leucaena leucocephala Species 0.000 description 3
108091006530 SLC28A1 Proteins 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
208000002495 Uterine Neoplasms Diseases 0.000 description 3
201000008395 adenosquamous carcinoma Diseases 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229960003668 docetaxel Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
201000003444 follicular lymphoma Diseases 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
201000002222 hemangioblastoma Diseases 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
201000003731 mucosal melanoma Diseases 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
201000000032 nodular malignant melanoma Diseases 0.000 description 3
201000002575 ocular melanoma Diseases 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
208000021284 ovarian germ cell tumor Diseases 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
201000003708 skin melanoma Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
206010046766 uterine cancer Diseases 0.000 description 3
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
206010000830 Acute leukaemia Diseases 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
206010060971 Astrocytoma malignant Diseases 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
206010004593 Bile duct cancer Diseases 0.000 description 2
208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
206010006143 Brain stem glioma Diseases 0.000 description 2
206010065305 Cancer in remission Diseases 0.000 description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
201000005171 Cystadenoma Diseases 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
208000021994 Diffuse astrocytoma Diseases 0.000 description 2
201000009051 Embryonal Carcinoma Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
206010018404 Glucagonoma Diseases 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
208000028572 Hereditary chronic pancreatitis Diseases 0.000 description 2
206010056976 Hereditary pancreatitis Diseases 0.000 description 2
206010067943 Hereditary papillary renal carcinoma Diseases 0.000 description 2
208000027927 Hereditary papillary renal cell carcinoma Diseases 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
206010023825 Laryngeal cancer Diseases 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
206010024218 Lentigo maligna Diseases 0.000 description 2
206010025312 Lymphoma AIDS related Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
206010051676 Metastases to peritoneum Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
208000003445 Mouth Neoplasms Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
DYCJFJRCWPVDHY-LSCFUAHRSA-N NBMPR Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(SCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 DYCJFJRCWPVDHY-LSCFUAHRSA-N 0.000 description 2
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
206010029488 Nodular melanoma Diseases 0.000 description 2
206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
201000007286 Pilocytic astrocytoma Diseases 0.000 description 2
208000007641 Pinealoma Diseases 0.000 description 2
208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
108091006551 SLC29A1 Proteins 0.000 description 2
102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 2
208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 2
206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 2
206010042971 T-cell lymphoma Diseases 0.000 description 2
208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
201000005969 Uveal melanoma Diseases 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
208000006336 acinar cell carcinoma Diseases 0.000 description 2
206010000583 acral lentiginous melanoma Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000003098 androgen Substances 0.000 description 2
206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
239000003560 cancer drug Substances 0.000 description 2
229960004117 capecitabine Drugs 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
201000007335 cerebellar astrocytoma Diseases 0.000 description 2
208000030239 cerebral astrocytoma Diseases 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
208000024207 chronic leukemia Diseases 0.000 description 2
229960002436 cladribine Drugs 0.000 description 2
208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
229960000928 clofarabine Drugs 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
208000002445 cystadenocarcinoma Diseases 0.000 description 2
208000012106 cystic neoplasm Diseases 0.000 description 2
229960000684 cytarabine Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000009110 definitive therapy Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
208000027858 endometrioid tumor Diseases 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
201000004753 familial renal oncocytoma Diseases 0.000 description 2
201000005306 familial renal papillary carcinoma Diseases 0.000 description 2
201000010972 female reproductive endometrioid cancer Diseases 0.000 description 2
201000001169 fibrillary astrocytoma Diseases 0.000 description 2
238000009459 flexible packaging Methods 0.000 description 2
229960000390 fludarabine Drugs 0.000 description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
201000005376 hepatoid adenocarcinoma Diseases 0.000 description 2
208000024635 hereditary kidney oncocytoma Diseases 0.000 description 2
208000029824 high grade glioma Diseases 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
206010022498 insulinoma Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000002357 laparoscopic surgery Methods 0.000 description 2
201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 2
208000037393 large granular lymphocyte leukemia Diseases 0.000 description 2
206010023841 laryngeal neoplasm Diseases 0.000 description 2
208000011080 lentigo maligna melanoma Diseases 0.000 description 2
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
208000030883 malignant astrocytoma Diseases 0.000 description 2
201000011614 malignant glioma Diseases 0.000 description 2
208000026037 malignant tumor of neck Diseases 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
206010027191 meningioma Diseases 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 2
208000004707 mucinous cystadenoma Diseases 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
208000002820 pancreatoblastoma Diseases 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
208000010918 peritoneal neoplasm Diseases 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000009101 premedication Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
229910052704 radon Inorganic materials 0.000 description 2
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
238000002271 resection Methods 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 2
208000000649 small cell carcinoma Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
201000005211 struma ovarii Diseases 0.000 description 2
208000030457 superficial spreading melanoma Diseases 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229940063683 taxotere Drugs 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
208000008732 thymoma Diseases 0.000 description 2
231100000816 toxic dose Toxicity 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000000239 visual pathway Anatomy 0.000 description 2
230000004400 visual pathway Effects 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010002412 Angiocentric lymphomas Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
206010073360 Appendix cancer Diseases 0.000 description 1
208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
206010007275 Carcinoid tumour Diseases 0.000 description 1
201000000274 Carcinosarcoma Diseases 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010072449 Desmoplastic melanoma Diseases 0.000 description 1
GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
102000045002 Equilibrative nucleoside transporter 2 Human genes 0.000 description 1
102100021468 Equilibrative nucleoside transporter 2 Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
208000021309 Germ cell tumor Diseases 0.000 description 1
208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
101000822017 Homo sapiens Equilibrative nucleoside transporter 2 Proteins 0.000 description 1
101100478240 Homo sapiens SPARC gene Proteins 0.000 description 1
101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
206010024305 Leukaemia monocytic Diseases 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
206010025342 Lymphoplasmacytoid lymphoma/immunocytoma Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
208000006395 Meigs Syndrome Diseases 0.000 description 1
206010027139 Meigs' syndrome Diseases 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
239000005041 Mylar™ Substances 0.000 description 1
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 1
201000006346 Neonatal Jaundice Diseases 0.000 description 1
206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
206010052399 Neuroendocrine tumour Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
206010031096 Oropharyngeal cancer Diseases 0.000 description 1
206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
101150118944 PRSS1 gene Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
206010048734 Phakomatosis Diseases 0.000 description 1
208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
206010034811 Pharyngeal cancer Diseases 0.000 description 1
206010050487 Pinealoblastoma Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
208000023146 Pre-existing disease Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
206010037127 Pseudolymphoma Diseases 0.000 description 1
201000008183 Pulmonary blastoma Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038111 Recurrent cancer Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108091006179 SLC29 Proteins 0.000 description 1
108091006544 SLC29A2 Proteins 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
206010042658 Sweat gland tumour Diseases 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000009365 Thymic carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000019297 Well-differentiated fetal adenocarcinoma of the lung Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
HSUDWURBWSUCOB-JPHWUADUSA-N ac1l907a Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-JPHWUADUSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000003915 air pollution Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000006431 amelanotic melanoma Diseases 0.000 description 1
239000003708 ampul Substances 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000002583 angiography Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
208000021780 appendiceal neoplasm Diseases 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
208000016894 basaloid carcinoma Diseases 0.000 description 1
201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
238000003766 bioinformatics method Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical class ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
201000002143 bronchus adenoma Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940001981 carac Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000011342 chemoimmunotherapy Methods 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000019506 cigar Nutrition 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
201000010276 collecting duct carcinoma Diseases 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000002016 colloidosmotic effect Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000000315 cryotherapy Methods 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
201000004434 cystic teratoma Diseases 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960002997 dehydrocholic acid Drugs 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
238000002283 elective surgery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
208000001991 endodermal sinus tumor Diseases 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
208000037902 enteropathy Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000002146 exchange transfusion Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
238000011223 gene expression profiling Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
102000034238 globular proteins Human genes 0.000 description 1
108091005896 globular proteins Proteins 0.000 description 1
GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
229940099347 glycocholic acid Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
201000006866 hypopharynx cancer Diseases 0.000 description 1
238000013388 immunohistochemistry analysis Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
208000015266 indolent plasma cell myeloma Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
201000009019 intestinal benign neoplasm Diseases 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
201000008893 intraocular retinoblastoma Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
201000007785 kidney angiomyolipoma Diseases 0.000 description 1
210000000244 kidney pelvis Anatomy 0.000 description 1
208000003849 large cell carcinoma Diseases 0.000 description 1
201000005274 large cell carcinoma with rhabdoid phenotype Diseases 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000011299 local ablative therapy Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
201000000014 lung giant cell carcinoma Diseases 0.000 description 1
201000000966 lung oat cell carcinoma Diseases 0.000 description 1
201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
208000021937 marginal zone lymphoma Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
201000000271 mature teratoma Diseases 0.000 description 1
238000002483 medication Methods 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
241000514897 mixed subtypes Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006894 monocytic leukemia Diseases 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
208000025189 neoplasm of testis Diseases 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
208000016450 non-cutaneous melanoma Diseases 0.000 description 1
208000015270 non-secretory plasma cell myeloma Diseases 0.000 description 1
201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000004287 null lymphocyte Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
201000008106 ocular cancer Diseases 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
201000006958 oropharynx cancer Diseases 0.000 description 1
229950001094 ortataxel Drugs 0.000 description 1
BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
230000036407 pain Effects 0.000 description 1
238000009116 palliative therapy Methods 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
201000003113 pineoblastoma Diseases 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000003476 primary myelofibrosis Diseases 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000004219 purine nucleobase group Chemical group 0.000 description 1
239000002718 pyrimidine nucleoside Substances 0.000 description 1
238000007674 radiofrequency ablation Methods 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
201000003804 salivary gland carcinoma Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
238000009094 second-line therapy Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
239000000779 smoke Substances 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
229940080274 sodium cholesteryl sulfate Drugs 0.000 description 1
LMPVQXVJTZWENW-KPNWGBFJSA-M sodium;[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].C1C=C2C[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 LMPVQXVJTZWENW-KPNWGBFJSA-M 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
208000037992 stage IV cutaneous melanoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000001321 subclavian vein Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
201000010965 sweat gland carcinoma Diseases 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
238000003325 tomography Methods 0.000 description 1
239000008181 tonicity modifier Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000009999 tuberous sclerosis Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
201000011294 ureter cancer Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 1
229960001661 ursodiol Drugs 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000002620 vena cava superior Anatomy 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1